Hot Life Science Investor Mandate 2: Foundation Allocates to Companies Working to Cure Retinal Diseases

20 Nov

A foundation based in the Eastern US typically makes allocations to companies in the range of $1-$8 million, and is capable of providing $10-$15 million over the investments lifetime. The firm primarily funds companies located in the United States but will consider opportunities located globally as well. The firm provides equity capital, and does look for a return, though percentages taken are generally less than more financially-motivated investors, and all profits are reinvested back into the fund. Ideally, the firm would like to allocate to 3-4 companies over the next 6-9 months.

The foundation’s mission is to fund research that will provide preventions, treatments and cures for the entire spectrum of retinal degenerative diseases. Currently, they are looking to fund companies in the therapeutics sector, and will consider companies working in areas of Small Molecules, Biologics, Gene Therapy, and Regenerative Medicine that target those indications. The firm primarily funds companies that are just preparing to enter the IND enabling stage, but they will consider companies in all stages of clinical trials.

The foundation often invests into companies that do not have complete management teams, and looks to utilize the foundations expertise and network in the retinal disease space to help companies grow. The foundation has many experts in the field that will help aid companies as well as a registry of potential patients for clinical trials.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: